Abstract:Objective: Post-stroke epilepsy (PSE) is associated with increased morbidity and mortality. Stroke-associated acute symptomatic seizures are an important risk factor: 20.8–34.3% of these patients will go on to develop PSE. Identifying these “high risk” individuals may result in earlier PSE diagnosis, treatment, and avoidance of seizure-related morbidity. This study was to identify predictors of PSE development in patients with stroke-associated acute symptomatic seizures. Participants and Methods: This was a retrospective cohort study of 167 patients with stroke-associated acute symptomatic seizures admitted to the Neurology Department of a tertiary Hospital of China, from 1 May 2006 to 30 January 2020. Both those with primary ischemic stroke and intracerebral hemorrhage were included in the study. Patient demographics, medical history, stroke-associated, and seizure-related variables were evaluated with univariable analysis and multivariable Cox regression analysis. PSE was defined as unprovoked seizures occurring > 7 days post-stroke. Data points were extracted from medical records and supplemented by tele-interview. Results: Of the 167 patients with stroke-associated acute symptomatic seizures, 49 (29.3%) developed PSE. NIHSS score > 14 [hazard ratio (HR) 2.98, 95% CI 1.57–5.67], longer interval from stroke to acute symptomatic seizures (days 4–7 post-stroke) (HR 2.51, 95% CI 1.37–4.59) and multiple acute symptomatic seizures (HR 5.08, 95% CI 2.58–9.99) were independently associated with PSE development. This association remained in the sub-analysis within the ischemic stroke cohort. In the sub-analysis of the hemorrhagic stroke cohort, multilobar involvement (HR 4.80, 95% CI 1.49–15.39) was also independently associated with development of PSE. Further, we developed a nomogram to predict individual risk of developing PSE following stroke-associated acute symptomatic seizures. The nomogram showed a C-index of 0.73. Conclusion: More severe neurofunctional deficits (NIHSS score > 14), longer interval from stroke to acute symptomatic seizures (days 4–7 post-stroke), and multiple acute symptomatic seizures were independently associated with development of PSE in patients with stroke-associated acute symptomatic seizures. This knowledge may increase clinical vigilance for development of PSE, facilitating rapid diagnosis and treatment initiation, and subsequently reduce seizure-related morbidity.

Research Advances in Post-stroke Seizure and Post-stroke Epilepsy

Advances in clinical research on post-stroke seizure

Research Status and Advances of Post-stroke Seizure and Post-stroke Epilepsy

The Progress of Poststroke Seizures

Pathophysiology, Diagnosis, Prognosis, and Prevention of Poststroke Epilepsy: Clinical and Research Implications

Poststroke Seizure and Epilepsy: A Review of Incidence, Risk Factors, Diagnosis, Pathophysiology, and Pharmacological Therapies

Clinical approaches for poststroke seizure: a review

Risk of Post-stroke Epilepsy Following Stroke-Associated Acute Symptomatic Seizures

Electroencephalogram findings in 10 patients with post-stroke epilepsy: A retrospective study

Applications of Electroencephalography in the Management of Stroke Patients

Association Between Different Acute Stroke Therapies and Development of Post Stroke Seizures

Incidence, Implications, and Management of Seizures Following Ischemic and Hemorrhagic Stroke

Post-stroke epilepsy and risk of all-cause mortality: A systematic review and meta-analysis of cohort studies

Post-stroke epilepsy

Stroke-related epilepsy

[Risk factors for post stroke epilepsy]

Incidence rate and risk factors of status epilepticus after stroke

The Research Progress of New Antiepileptic Drugs

Treating Post-stroke Epilepsy in a Patient With Multiple Comorbidities

Role of the glymphatic system and perivascular spaces as a potential biomarker for post‐stroke epilepsy

Detailed risks and characteristics of postepilepsy stroke in non-traumatic adult-onset epilepsy